Stocks · News reference
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Turn Therapeutics Inc. announced that its GX-03 therapy has been recognized as the 'Developmental Immunology Solution of the Year' in the 2026 BioTech Breakthrough Awards.
MGE Energy, Inc. announced an increase in third-quarter earnings and revenue compared to the same period in the previous year.
Filed: 2026-11-04 AccNo: 0001193125-26-446285 Size: 364 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Apollo Global Management (APO) reported Q3 2026 adjusted earnings of $2.15 per share, missing the consensus estimate of $2.21, causing shares to dip 3.5%. While segment revenues rose 20% year-over-year to $1.37 billion and fee-generating AUM surged 28% to $880 billion, higher expenses increased 15% year-over-year, offsetting gains. The company carries a Zacks Rank #4 (Sell) rating.
Rothschild & Co Reburn has increased its price target for Ares Management Corporation shares from $128 to $129.
BMO Capital has increased its price target for Ares Management Corporation from $130 to $133.